REFERENCES

1. JD Feuerstein et al. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology 2020; 158:1450. doi:10.1053/j.gastro.2020.01.006
2. JD Feuerstein et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. Gastroenterology 2021; 160:2496. doi:10.1053/j.gastro.2021.04.022
3. DT Rubin et al. ACG clinical guideline: ulcerative colitis in adults. Am J Gastroenterol 2019; 114:384. doi:10.14309/ajg.0000000000000152
4. AC Ford et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:601. doi:10.1038/ajg.2011.67
5. G-T Ho et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006; 24:319. doi:10.1111/ j.1365-2036.2006.02974.x
6. Budesonide (Uceris) for ulcerative colitis. Med Lett Drugs Ther 2013; 55:23.
7. Budesonide rectal foam (Uceris) for ulcerative colitis. Med Lett Drugs Ther 2015; 57:154.
8. GR Lichtenstein et al. ACG clinical guideline: management of Crohn's disease in adults. Am J Gastroenterol 2018; 113:481. doi:10.1038/ajg.2018.27
9. A Timmer et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016; 5:CD000478. doi:10.1002/14651858. cd000478.pub4
10. N Chande et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2015; 10:CD000067. doi:10.1002/14651858.cd000067.pub3
11. JWD McDonald et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2014; 8:CD003459. doi:10.1002/14651858.cd003459.pub4
12. AM Abbas et al. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort. Am J Gastroenterol 2014; 109:1781. doi:10.1038/ajg.2014.298
13. M Lemaitre et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017; 318:1679. doi:10.1001/jama.2017.16071
14. R Panaccione et al. Clinical benefit of long-term adalimumab treatment in patients with Crohn's disease following loss of response or intolerance to infliximab: 96-week efficacy data from GAIN/ADHERE trials. J Crohns Colitis 2018; 12:930. doi:10.1093/ecco-jcc/jjy050
15. JF Colombel et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383. doi:10.1056/nejmoa0904492
16. R Panaccione et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146:392. doi:10.1053/j.gastro.2013.10.052
17. Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014; 56:86.
18. BG Feagan et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369:699. doi:10.1056/NEJMoa1215734
19. WJ Sandborn et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013; 369:711. doi:10.1056/NEJMoa1215739
20. EV Loftus Jr et al. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52:1353. doi:10.1111/apt.16060
21. T Card et al. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. Aliment Pharmacol Ther 2020; 51:149. doi:10.1111/apt.15538
22. J Meserve et al. Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2019; 17:1533. doi:10.1016/j.cgh.2018.09.035
23. Ustekinumab (Stelara) for Crohn's disease. Med Lett Drugs Ther 2017; 59:5.
24. BE Sands et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381:1201. doi:10.1056/nejmoa1900750
25. B Feagan et al. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016; 375:1946. doi:10.1056/nejmoa1602773
26. Risankizumab (Skyrizi) – an IL-23 antagonist for Crohn's disease. Med Lett Drugs Ther 2022; 64:205.
27. NIH. A multicenter, randomized, double-blind, placebo controlled induction study to evaluate the efficacy and safety of risankizumab in participants with moderately to severely active ulcerative colitis. NCT03398148. Available at: https://bit.ly/3PoT0NH. Accessed June 22, 2023.
28. NIH. A study to assess the efficacy and safety of risankizumab in participants with ulcerative colitis. NCT03398135. Available at: https://bit.ly/43OI14k. Accessed June 22, 2023.
29. G D'Haens et al. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet 2022; 399:2015. doi:10.1016/s0140-6736(22)00467-6
30. M Ferrante et al. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet 2022; 399:2031. doi:10.1016/s0140-6736(22)00466-4
31. Upadacitinib (Rinvoq): a second JAK inhibitor for ulcerative colitis. Med Lett Drugs Ther 2022; 64:142.
32. WJ Sandborn et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376:1723. doi:10.1056/nejmoa1606910
33. S Danese et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet 2022; 399:2113. doi:10.1016/s0140-6736(22)00581-5
34. EV Loftus Jr et al. Upadacitinib induction and maintenance therapy for Crohn's disease. N Engl J Med 2023; 388:1966. doi:10.1056/nejmoa2212728
35. MT Abreu. JAK1 inhibition to treat Crohn's disease. N Engl J Med 2023; 388;2005. doi:10.1056/nejme2301147
36. Ozanimod (Zeposia) for ulcerative colitis. Med Lett Drugs Ther 2021; 63:147.
37. WJ Sandborn et al. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2021; 385:1280. doi:10.1056/nejmoa2033617
38. BE Sands et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381:1215. doi:10.1056/nejmoa1905725
39. N Narula et al. Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis. Clin Gastroenterol Hepatol 2022; 20:1588. doi:10.1016/j.cgh.2021.07.038
40. JS Lasa et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 2022; 7:161. doi:10.1016/s2468-1253(21)00377-0
41. HK Hyun et al. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment. BMC Gastroenterol 2022; 22:143. doi:10.1186/s12876-022-02225-w
42. A Buisson et al. Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent. Aliment Pharmacol Ther 2023; 57:676. doi:10.1111/apt.17305
43. T Straatmijer et al. Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study. Clin Gastroenterol Hepatol 2023; 21:182. doi:10.1016/j.cgh.2022.04.038
44. BE Sands et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 2022; 399:2200. doi:10.1016/s0140-6736(22)00688-2
45. N Narula et al. Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn's disease. Am J Gastroenterol 2022; 117:1106. doi:10.14309/ajg.0000000000001795